Compare Cronos Group Inc (CRON) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Gitlab Inc — how do they compare? Cronos Group Inc trades at $3.18 (market cap $1.14B), while Gitlab Inc trades at $40.8 (market cap $7.11B). The key difference: Gitlab Inc is far larger — about 6.2× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| CRON | GTLB | |
|---|---|---|
Market Cap | $1.14B | $7.11B |
Sector | Health | Technology |
52-Week High | $3.27 | $51.04 |
52-Week Low | $2.30 | $19.42 |
Enterprise Value | $341.13M | $5.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.165, up 5.5% with bullish technical signals from moving averages. The company shows strong revenue growth, with Q2 2026 beating expectations with $0.09 EPS versus $0.01 expected, and record quarterly performance. However, profitability remains inconsistent with negative net income in 2025. Analyst sentiment is mixed with 60% hold ratings, reflecting cautious optimism amid competitive pressures.
Outlook is cautiously optimistic with international expansion driving growth, but execution risks and cannabis sector volatility persist. The stock offers growth potential through European market penetration and product innovation, though investors should monitor margin improvements and competitive dynamics closely.
GitLab (GTLB) trades at $40.93, up 0.49% today, with a bullish technical signal from moving averages but overbought RSI readings above 90. The company reported strong revenue growth, reaching $759 million in 2025, and has beaten EPS estimates for three consecutive quarters. Recent news highlights its leadership in DevSecOps and AI-driven platform enhancements, including the launch of GitLab 19.2 and a collaboration with Google Cloud.
Outlook remains mixed; analyst consensus is cautious with a $32.92 price target below the current price, citing high valuation multiples like a P/E of 521.22. Risks include persistent negative cash flow and profitability challenges, though growth in AI and enterprise adoption offers long-term potential. Investors should weigh high valuation against robust revenue expansion and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
